Nissan Medical Industries Ltd (TLV:NISA)
Israel
· Delayed Price · Currency is ILS · Price in ILA 862.20
-16.40 (-1.87%)
Apr 28, 2026, 5:24 PM IDT
Nissan Medical Industries Income Statement
Financials in millions ILS. Fiscal year is January - December.
Millions ILS. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Revenue | 651.78 | 664.08 | 733.91 | 684.65 | 668.37 | Upgrade
|
| Revenue Growth (YoY) | -1.85% | -9.52% | 7.20% | 2.44% | -7.36% | Upgrade
|
| Cost of Revenue | 563.41 | 566.06 | 598.14 | 601.37 | 523.95 | Upgrade
|
| Gross Profit | 88.37 | 98.02 | 135.78 | 83.28 | 144.42 | Upgrade
|
| Selling, General & Admin | 66.61 | 68.35 | 73.14 | 85.19 | 78.54 | Upgrade
|
| Other Operating Expenses | -4.02 | -0.01 | 1.26 | -0.15 | 0.07 | Upgrade
|
| Operating Expenses | 62.59 | 68.35 | 74.4 | 85.04 | 78.61 | Upgrade
|
| Operating Income | 25.78 | 29.68 | 61.37 | -1.77 | 65.81 | Upgrade
|
| Interest Expense | -11.99 | -13.34 | -21.27 | -10.02 | -7.28 | Upgrade
|
| Interest & Investment Income | 0.26 | 0.47 | 0.18 | 0.01 | - | Upgrade
|
| Earnings From Equity Investments | 0.18 | 1.3 | -7.06 | -0.64 | 4.62 | Upgrade
|
| Currency Exchange Gain (Loss) | -0.58 | 1.51 | 0.05 | -8.33 | 3.19 | Upgrade
|
| Other Non Operating Income (Expenses) | -3.99 | -4.46 | -5.47 | -2.44 | -1.28 | Upgrade
|
| EBT Excluding Unusual Items | 9.66 | 15.15 | 27.81 | -23.18 | 65.06 | Upgrade
|
| Impairment of Goodwill | - | - | - | -23.79 | - | Upgrade
|
| Gain (Loss) on Sale of Investments | 0.37 | 0 | 0.01 | -0.05 | 5.39 | Upgrade
|
| Pretax Income | 10.02 | 15.15 | 27.82 | -47.02 | 70.45 | Upgrade
|
| Income Tax Expense | 1.33 | 1.35 | 8.78 | 0.27 | 13.29 | Upgrade
|
| Earnings From Continuing Operations | 8.7 | 13.8 | 19.04 | -47.29 | 57.16 | Upgrade
|
| Minority Interest in Earnings | -4.52 | -5.9 | -13.39 | 11.24 | -21.14 | Upgrade
|
| Net Income | 4.17 | 7.91 | 5.65 | -36.05 | 36.01 | Upgrade
|
| Net Income to Common | 4.17 | 7.91 | 5.65 | -36.05 | 36.01 | Upgrade
|
| Net Income Growth | -47.22% | 39.95% | - | - | -36.65% | Upgrade
|
| Shares Outstanding (Basic) | 9 | 9 | 9 | 9 | 9 | Upgrade
|
| Shares Outstanding (Diluted) | 9 | 9 | 9 | 9 | 9 | Upgrade
|
| EPS (Basic) | 0.46 | 0.87 | 0.62 | -3.97 | 3.96 | Upgrade
|
| EPS (Diluted) | 0.46 | 0.87 | 0.62 | -3.97 | 3.93 | Upgrade
|
| EPS Growth | -47.20% | 39.90% | - | - | -37.13% | Upgrade
|
| Free Cash Flow | 36.53 | 20.74 | 95.9 | 2.49 | 9.82 | Upgrade
|
| Free Cash Flow Per Share | 4.02 | 2.28 | 10.56 | 0.28 | 1.08 | Upgrade
|
| Dividend Per Share | 1.820 | 0.750 | - | - | 0.440 | Upgrade
|
| Dividend Growth | 142.67% | - | - | - | -56.00% | Upgrade
|
| Gross Margin | 13.56% | 14.76% | 18.50% | 12.16% | 21.61% | Upgrade
|
| Operating Margin | 3.96% | 4.47% | 8.36% | -0.26% | 9.85% | Upgrade
|
| Profit Margin | 0.64% | 1.19% | 0.77% | -5.27% | 5.39% | Upgrade
|
| Free Cash Flow Margin | 5.60% | 3.12% | 13.07% | 0.36% | 1.47% | Upgrade
|
| EBITDA | 48.45 | 53 | 92.52 | 26.88 | 91.4 | Upgrade
|
| EBITDA Margin | 7.43% | 7.98% | 12.61% | 3.93% | 13.68% | Upgrade
|
| D&A For EBITDA | 22.67 | 23.32 | 31.14 | 28.65 | 25.6 | Upgrade
|
| EBIT | 25.78 | 29.68 | 61.37 | -1.77 | 65.81 | Upgrade
|
| EBIT Margin | 3.96% | 4.47% | 8.36% | -0.26% | 9.85% | Upgrade
|
| Effective Tax Rate | 13.25% | 8.92% | 31.56% | - | 18.87% | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.